| Peter
Nicholas
Mr. Peter Nicholas is the co-founder and chairman of Boston
Scientific Corporation. He is a trusted adviser to Dr. Shen,
the inventor of the Multifunction Cardio Gram (MFG) who
also holds the patent. As a colleague of the late Edmund
T. Pratt, Jr., a founder and early investor in MCG
and former CEO/Chairman of Pfizer Pharmaceuticals, Mr. Nichols
has first-hand knowledge of the clinical utility of novel
technologies. Mr. Nicholas was personally responsible for
introducing MFG technology to Dr. Eberhard Grube (please
see below), an internationally recognized key opinion leader
in the area of interventional cardiology who later conducted
peer-reviewed clinical trials on the system.
Joan Louney Wakeman
Executive Administrator to Pete M. Nicholas
Chairman of the Board
Boston Scientific Corporation
One Boston Scientific Place
Natick, MA 01760
508-650-8401
508-650-8955 (facsimile)
E-Mail: joan.louneywakeman@bsci.com
John Abele
Mr. John Abele is the co-founder and director of Boston
Scientific Corporation. Mr. Abele was one of the colleagues
of Mr. Pratt and Mr. Nicholas who underwent early testing
of the Multifunction Cardio Gram (MFG). Mr. Abele witnessed
the utility of the device in detecting serious subclinical
cardiovascular conditions among colleagues who subsequently
had ‘unanticipated’ acute coronary events within
the year, despite non-diagnostic test results and reports
of good health on their annual comprehensive executive physical
examinations.
Linda Eckard
Executive Assistant to John Abele
Boston Scientific Corporation
One Boston Scientific Place
Natick, MA 01760
508-650-8306
508-650-8955 (facsimile)
E-Mail: Linda.Eckard@bsci.com
Dr. Eberhard Grube
Dr. Eberhard Grube is Chief of the Department of Cardiology
and Angiology at the Heart Center Siegburg in Germany and
is Consulting Professor of Medicine at Stanford. He is internationally
renowned as an innovator in the development and testing
of novel devices and procedures in the cardiovascular arena.
Over the past decade he has led some of the initial clinical
trials of drug-eluting stents, percutaneous closure devices,
new atherectomy techniques, catheter-based valve insertion
procedures as well as the recognition and treatment of vulnerable
plaque. Dr. Grube has performed over 350 cardiac surgical
procedures and was the Principal Investigator of MCG’s largest clinical trial which included nearly
1,000 patients.
Prof. Dr. Med. Eberhard Grube
Herzzentrum Siegburg
Ringstraße 49
Siegburg, Germany 53721
Phone: +4922241182322
Contact his assistant:
Email: Kroschel@Klinikum-Siegburg.de
Dr. Yuk Law
Yuk Law, MD, serves as Medical Director of Cardiac Transplant
and Heart Failure at Seattle Children’s Heart Center
which is ranked as one of the top cardiac and cardiac surgery
programs in the country by U.S. News & World Report.
Dr. Yuk Law is a contributing author on pediatric heart
failure to the field’s most authoritative text, Congestive
Heart Failure. His fellowship training in both pediatric
cardiology and immunobiology allows him to take a more comprehensive
approach to the care of patients with cardiopulmonary failure
who require transplantation. Dr. Law states: “Even
though I am not a biomedical engineer and may not be able
to lecture comprehensively on this novel technology, I think
the new technology from MCG is extremely exciting
on two fronts. First, the development of methodology that
allows constant input of new data in real-time as it is
collected in the field, constantly improves the test’s
diagnostic utility while improving its accuracy. The concept
of early detection also plays a key role in proteogenomics
with the use of tools such as micro array gene analysis
for the early recognition of rejection. As more data is
fed into its neural networks, the algorithm matures not
only in diagnostic accuracy, but also in terms of the test’s
utility, thereby increasing the spectrum of indications.
The second is that this type of testing is great for screening
large populations. Infants with heart disease can be delivered
anywhere, and I mean anywhere! Every clinician knows it
is not that easy to make a diagnosis of serious heart disease
and many conditions will not manifest until closure of the
ductus arteriosus, just when the baby goes home after a
C-section for example at around 2-5 days of life. Infants
have been lost because of this problem. The EKG is notorious
for not being sensitive or specific enough and it really
comes down to echocardiography. I am in the midst of publishing
a study using BNP (a cardiac hormone) for screening purposes,
but the sensitivities could be better and there are some
drawbacks with this test in the neonate population. There
are EKG abnormalities associated with certain congenital
heart diseases but we need a way to improve the detection
rate and differentiate it from either infection or lung
disease, commonly seen in the newborn period. There are
also more infants born than there are adults with coronary
artery disease, so the scope of the problem is potentially
quite large. We already do state funded newborn screening
for certain kinds of errors of metabolism, like PKU, etc.,
but we don’t do it for heart conditions and the problem
is just waiting for someone to figure out a practical, simple,
and relatively inexpensive way to screen these neonates.
This kind of approach can obviously lead to other applications
in pediatric cardiology, such as identifying rejection,
etc. I am hoping we can develop the same approach for babies
with congenital heart disease as is used to detect coronary
artery disease.”
Dr Yuk Law at The Children’s Hospital and Regional
Medical Center
G-0035 - Cardiology Administration
4800 Sand Point Way NE
Seattle, W A 98105
Phone: (206) 987-2380
Email: yuk.law@seattlechildrens.org
|
|
Dr. Michael
Imhoff
Dr. Michael Imhoff is a board certified surgeon and specialist
in intensive care with 18 years clinical practice at one
of the largest hospitals in Europe. He holds a PhD in Medical
Informatics and Statistics and is a reader at the Medical
School of the Ruhr-University Bochum, Germany. Dr. Imhoff
has authored or co-authored over 300 national and international
monographs, books, book chapters, scientific lectures and
posters. His areas of research have included surgical intensive
care medicine, patient monitoring clinical data management,
statistical time series analysis and related methods, artificial
intelligence in medicine, health care economics, macro and
micro allocation of medical resources as well as rationing
of health care. He is a strategic consultant to Dräger
Medical and Siemens Medical, and in that context, he performed
an extensive analysis of MCG data.
Dr. Michael Imhoff, M.D., PhD
Department for Medical Informatics, Biometrics and Epidemiology
Ruhr-University Bochum
Bochum D-44780, Germany
Home Office: Am Pastorenwaelchen 2
Dortmund D-44229, Germany
Phone: +49-231-973022-0
Mobile: +49-171-7411198
Email: Mike@imhoff.de
Dr. H. Robert Silverstein
Dr. H. Robert Silverstein is a practicing cardiologist who
has used MCG for 3 years. He is board certified in cardiovascular
disease, internal medicine, and preventive medicine, and
is also a Fellow of the American College of Cardiology and
the American College of Preventive Medicine.
H. Robert Silverstein, M.D.
Medical Director, Preventive Medicine Center
1000 Asylum Ave. Suite 2109
Hartford, CT 06105
Phone: (860) 549-3444
Email: HRS@wellness-md.com
Dr. Wilbert Aronow
Wilbert Aronow, MD is Professor of Medicine at New York
Medical College and Head of teaching and clinical research
cardiology at Westchester Medical Center where the Company’s
first clinical trial was conducted from 2001-2002. Dr. Aronow
is a renowned researcher and editor of many medical peer
review journals.
Wilbert Aronow, M.D., F.A.C.C. Contact: Ms. Emily Noriega
Division of Cardiology, Westchester Medical Center
Macy Pavilion West
Valhalla, NY 10595
Phone: 914-493-5311 (Voice Mail)
Email: WSARONOW@aol.com
Dr. Lance Austein
Dr. Lance Austein is board certified in internal medicine
and has a thriving primary care practice in Brooklyn. He
is also highly regarded by his peers for his leadership
in adapting new technologies and therapies that might be
of clinical benefit in managing his patient population.
Dr. Austein’s enthusiasm for MCG is based on how it
has improved the diagnostic capability of his practice.
For example, he referred a patient for evaluation of anginal
chest pain to a cardiology group for further diagnostic
evaluation where all stress tests were within normal limits.
The patient returned to his office, where his MCG test was
‘strongly’ positive for Coronary Artery Disease.
Dr. Austin referred his patient to Columbia Presbyterian
Medical Center for a coronary angiogram, which confirmed
the results obtained from the MCG test. The patient underwent
PTCA and stent insertion for a discrete critical proximal
LAD stenosis and thereafter remained free of chest pain.
The follow up MCG test showed no further evidence of ischemia.
Dr. Austein has since become a strong advocate.
Lance Austein, MD
Modern Medical PC
1913 Ave. Z
Brooklyn, NY 11235
Office: 718-934-6661
Fax: 718-891-1417
Email: Dr .lance@Gmail.com
Dr. Murray Werzberger
Dr. Murray Werzberger, an associate of Dr. Austein’s,
is also a senior partner of Modern Medical PC and a leader
in the medical community. He was responsible for the formation
of this large group practice of primary care physicians.
The use of the Multifunction Cardio Gram (MFG) has so enhanced
his group’s capacity to practice early cardiovascular
detection and prevention that, as a result, his group has
considered hiring several cardiologists with interest in
cardiovascular prevention as part of their next expansion.
Dr. Werzberger advocates the use of this technology in primary
care practice.
Murray Werzberger, MD
Modern Medical PC
2044 Ocean Ave.
Brooklyn, NY 11230
Office: 718-998-2222
Fax: 718-998-2693
Email: mjzsw@aol.com
|
